SIHUAN PHARM (00460) rose more than 9% again. As of writing, the stock was up 8.9% to HK$1.59, with a turnover of HK$150 million. On the news front, SIHUAN PHARM recently announced that six new specifications of the polylactic acid facial filler (commonly known as the "Youth Shot"), independently developed by its subsidiary Meiyan Kongjian Biotechnology (Jilin) Co., Ltd., have been officially approved by China's National Medical Products Administration. Founder Securities previously noted that the company is achieving breakthroughs in its aesthetic medicine pipeline and partnerships, coupled with the value realization of its innovative drugs, leading to a further acceleration of its dual-growth engine. The brokerage pointed out that the current pipeline portfolio is accelerating its contribution: botox continues to deliver robust, high growth steadily; new products like the Youth Shot and the "Maiden Shot" are beginning to ramp up; and the new动能素水光 product is expected to become a new growth driver. Subsequent pipelines, including regenerative products, collagen-based products, energy-based devices, and weight-loss products, are expected to be continuously launched and commercialized, providing substantial long-term momentum. Furthermore, recent discussions surrounding an outbreak of Nipah virus in India have drawn attention. Back in 2020, SIHUAN PHARM announced a framework cooperation agreement with India-registered Hetero Drugs Limited in the pharmaceutical sector. According to the cooperation framework, this partnership involves close collaboration and joint development in areas such as research and development, product registration, technology transfer, raw material supply, localized production, and sales of drugs for cardiovascular and cerebrovascular diseases, central nervous system disorders, and anti-infectives, including drugs for the novel coronavirus (2019-nCoV).